Treatments for HER2-positive stage III lung cancer after chemoradiotherapy
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two medications, trastuzumab rezetecan and adebrelimab, given alone or together, for people with a specific type of stage III lung cancer that has a HER2 change. The goal is to see if these treatments can help control the cancer after standard chemotherapy and radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have non-small cell lung cancer that is stage III and cannot be removed with surgery.
- Your cancer has a HER2 mutation or high levels of HER2 protein.
- You have already completed at least two cycles of chemotherapy with radiation therapy.
- You are able to perform daily activities with some help (ECOG 0-1).
- You have not had prior treatment with HER2-targeted antibody-drug conjugates or HER2 tyrosine kinase inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two study drugs for a type of lung cancer that has a specific genetic change (HER2). Doctors want to see if this combination can help treat the cancer when it is advanced.
This trial tests a new combination of drugs (trastuzumab deruxtecan, pembrolizumab, and chemotherapy) as a first treatment for people with advanced non-small cell lung cancer that has high levels of the HER2 protein. The goal is to see if this combination works better than current options.
This study tests whether combining chemotherapy with immunotherapy before and after chemoradiation helps people with stage III lung cancer that can be removed by surgery. It might improve how well treatment works and reduce the chance of cancer coming back.
This trial tests two drugs together (SHR-A1811 and pertuzumab) to see if they can shrink or control lung cancer that has a HER2 change and has already been treated once before. It is a second-line option that targets the cancer specifically.
This trial tests a targeted drug, trastuzumab deruxtecan, for people with non-small cell lung cancer that has a specific HER2 gene change. The treatment is given before surgery to shrink the tumor and make it easier to remove.
This study tests a combination of two targeted drugs (envafolimab and disitamab vedotin) plus chemotherapy (carboplatin) given before surgery for lung cancer that has a HER2 mutation. The goal is to see if this can shrink the tumor and improve outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.